Biotechnology
MannKind (MNKD) has been on a run as of late and the news after the close on Friday helped shares put in another solid day yesterday, with shares rising nearly 15% on the session. The shares hit another 52-week high on the session before closing a few pennies off of that level at $7.63 and volume was quite strong with 19.1 million shares traded. Timelines are developing here which should reward investors further and we now know that the company will release follow up data on AFREZZA later this summer. This looks like one of the biotech names that will need to be watched this year as this could be a very large blockbuster drug.
The drug looks promising and investors have been pushing shares higher. This summer will tell us a lot more about the diabetes drug AFREZZA.
http://seekingalpha.com/article/1479371-social-networking-stocks-faltering-and-the-volatile-biotechs?source=google_news
